The global epigenetics market size was valued at USD 5.25 billion in 2017. It is estimated to register a CAGR of 19.7% during the forecast period. The increasing prevalence of cancer and other chronic diseases along with the rising geriatric population is poised to bolster the growth of the market.
The presence of organizations such as the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institute of Health (NIH) is positively influencing the growth of the market. These organizations are promoting funding and support to R&D and product development exercises pertaining to the field of epigenetics. NIH funds epigenetics research through a common fund epigenomics program, which actively supports new epigenetic research worldwide.
Rising needs to understand epigenetic modifications at the molecular level and development of therapeutic solutions are likely to motivate these organizations to fund research and development programs. In addition, endeavors such as the Epidemiology and Genomics Research Program (EGRP) grants incentives to research activities that are working towards an understanding of cancer causes and their related outcomes.
According to NCI, the estimated number of cancer deaths in the U.S. is 163.5 per 100,000 men and women per year. The International Cancer Genome Consortium (ICGC) is focusing on obtaining genomic description, epigenomic changes, and transcriptomic changes in different types of tumors.
The Encyclopedia of DNA Elements (ENCODE) project was launched by the U.S. national human genome research institute with an objective to identify all the human genome sequence functional elements. The International Human Epigenome Consortium (IHEC), built by NIH is also involved in the development of epigenomic data generation and analysis, which can be made useful for epigenomic researchers. Majorly, epigenetics research is focusing on the identification of treatment options for various types of tumors.
The market is majorly driven by the increasing prevalence of oncology, rising demand for early diagnostic procedures, growing global geriatric population, and increasing usage of epigenetic biomarkers at various stages of cancer. Increasing usage of combination biomarkers and growing need for effective & early diagnostic procedures for cancer are some of the factors expected to boost the market growth at a significant rate.
Due to the significance of epigenetics in the COVID-19 research, the Covid-19 pandemic has had a substantial impact on epigenetics market growth. According to a study published on BioMed Central, Epigenetic modifications may play an important role in the emergence of coronavirus illness consequences. Although, a number of therapy based on epigenetics are being examined, more research is necessary to find an effective vaccine as well as safer therapeutic options, including epigenetic treatments, to counter this viral pandemic. As a result, more epigenetics will be used in the identification of COVID-19 infection therapeutics, which is likely to fuel market expansion throughout the projection period.
An increase in the geriatric population is anticipated to increase market growth. As per WHO, the global population pertaining to the age group 65 years and above is expected to increase from 1 billion in 2019 to about 1.4 billion by 2030 and 2.1 billion by 2050, with developing countries accounting for a significant increase. Aging is considered the greatest risk factor for cardiovascular and neurological diseases; therefore, is anticipated to accelerate the risk of developing these diseases. Moreover, aging affect the immune system and increase the risk of getting infectious diseases. Furthermore, the growing geriatric population in Asian countries such as China, Japan, and India with large untapped potential is expected to fuel the market growth during the forecast period.
Furthermore, major technologies used in epigenetics are DNA methylation and modification of histones. Many different enzymes such as Histone Deacetylases (HDACs) and histone methyltransferases modify histones. Inhibitors of these enzymes prove to be potent biomarkers for the R&D of epigenetic drugs. There is increased focus on therapeutic segment of the epigenetic field. Many biotechnology & pharmaceutical companies and academic research organizations are collaborating to promote the growth of this industry. This is one of the high-impact rendering drivers of epigenetics market.
Therapeutic drugs for epigenetic-based disorders are developed on the basis of identification and validation of specific biomarkers. Most of the diagnostics companies face difficulties in this area, which proves to be a critical restraint for the growth of epigenetics market. Extensive need for research and inadequate R&D facilities are expected to restrain the market growth during the forecast period.
High R&D cost for developing novel products and stringent approval process is hampering the market growth. Novel epigenetic drugs need to be approved by concerned regulatory authorities before commercialization. This drug approval framework is time-consuming and stringent. There are no clear regulatory policies for the diagnostic sector in emerging economies, such as China and India, where the diagnostic market has great growth potential due to the presence of a large patient pool. However, the lack of skilled labor and inadequate health insurance coverage in remote areas are some of the key restraints affecting the growth of this market.
Based on products, the reagents dominated the market in 2017. Histone and DNA modifiers are the major types of reagents used for epigenetics. Some of the common epigenetic reagents are antibodies, PCR reagents, histones, primers, electrophoresis reagents, nucleic acid analysis reagents, and buffers. PyroMark Q24 is one of the advanced reagents featuring advanced pyrosequencing chemistry to provide even better real-time sequence-based detection and quantification than before.
The existence of a number of technology platforms facilitates analysis at gene, protein, or cellular levels, which encourages innovation in the global marketplace. Polymerase chain reaction (PCR) has helped establish a platform for genomic. Gene regulation is impacted by epigenetic factors such as chromatin structure, DNA methylation, and non - coding RNAs. The life sciences and analytical tools market is greatly influenced by the wide use of reagents.
The kits segment, on the other hand, is expected to post the highest CAGR during the forecast period. Ready - to - use kits are manufactured by many biotechnology companies for the detection of epigenetic modifications. Kits available in the market range from kits for nucleic acid purification, analysis of DNA methylation status, and detection of histone modifications by various enzymes to kits for chromatin immunoprecipitation. Epigenetic diagnostic kits are used for the diagnosis of disorders due to epigenetic modifications in the early stages and during treatment to check the efficacy of therapeutics. They work on the basis of immunoprecipitation by the involvement of modification - specific monoclonal antibodies.
The market, on the basis of technology, can be divided into DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microRNA modification, and chromatin structures. DNA methylation accounted for the leading share in the epigenetics market in 2017. DNA methylation is the covalent addition of a methyl group in cytosine ring, which leads to inhibition of transcription. Sensitive bisulphite modification followed by PCR is called methylation-sensitive PCR (MSP).
Real-time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles are variations of MSP. Currently, quantitative methods such as allele-specific bisulphite sequencing, southern-based method, bisulphite pyrosequencing, and bisulphite PCR followed by MALDI - TOF MS are also useful for DNA methylation. Advancements in technologies are increasingly enabling assessment of locus-specific DNA methylation on a genome-wide scale.
Histone Acetylation is expected to experience the fastest growth over the forecast period owing to its enhanced efficacy due to the introduction of novel mechanisms. It is enzymatic incorporation of an acetyl group to lysine residues. Histone acetylation is involved in the control of cellular processes such as gene silencing, chromatin transcription and dynamics, the progression of cell cycle, differentiation, apoptosis, DNA replication, neuronal repression, nuclear import, and DNA repair. Enzymes involved in histone acetylation are Histone Acetyl Transferases (HATs) and enzymes involved in deacetylation are histone deacetylases (HDACs).
Oncology was the leading revenue contributor in the global market, accounting for approximately 70.0% of the market in 2017. Increasing prevalence of cancer worldwide along with rising cases of deaths due to the disease is contributing to the growth of the segment. Moreover, the introduction of new products and potential commercialization of products currently in the pipeline in the near future are projected to trigger the growth of the segment.
Hypermethylation and epigenetic silencing are known as epimutations, occurring due to epigenetic changes. Epimutations have been known to be involved in etiology of cancers. Extensive R&D is going on for detecting epimutations, specifically related to silencing of tumor suppressor genes and the activation of oncogenes. Unlike regular mutations, epimutations are reversible in nature.
Non-oncology is anticipated to register a higher CAGR during the forecast period. The growth of the segment can be attributed to rigorous R&D initiatives undertaken by private institutions and biopharmaceutical companies for the identification of epigenetic markers related to these disorders. Epigenetic modifications are being proved to be the base of several non - oncology disorders such as metabolic disorders, neurodegenerative disorders, and infectious diseases. Extensive research is undertaken by private institutions and biopharmaceutical companies for the detection of biomarkers for drug development.
North America held the largest market share of 38.18% and is expected to maintain its position during the forecast period, majorly due to the massive government's considerable financing for epigenetics research. Furthermore, the existence of improved healthcare facilities and advances in diagnostic processes are some of the factors driving the regional market growth. Furthermore, increased patient awareness of the availability of advanced products is another factor contributing to the region's dominant market position.
In the U.S., there is a growing requirement for the development of cancer medicines, and many investments are being made in the awareness of cancer genetics, which is projected to boost the market's growth in the country. Cancer is the second leading cause of death in the country. In 2020, there were around 602,350 cancer deaths in the U.S. In addition, increasing funding for cancer genomics in the U.S. will result in increased acceptance of epigenetics in research, which will drive market expansion over the projection period.
Due to the sheer increased occurrence of chronic diseases that necessitate precise diagnosis, Europe held the second largest share of the epigenetics market. According to the GLOBOCAN 2020, Europe had 4,398,443 new cancer cases in 2020. Furthermore, during the projected period, the region's expanding merger and acquisition activity will have a significant impact on market value.
During the projected period, the market in Asia Pacific region is expected to grow at the fastest rate. In addition, the Asia Pacific market is expected to rise owing to increasing funding for research & development activities by the government, increased prevalence of cancer, and increasing investment of market players in the region. According to research conducted by the WHO, India had approximately 1.16 million new cases of cancer in 2018, with one in every ten Indians obtaining cancer at some point in their lifespan and one in every 15 died from cancer.
Key players in this industry are Roche Diagnostics; Thermo Fisher Scientific, Inc.; Eisai Co. Ltd.; and Novartis AG. Some of the major players are focusing on expanding their businesses in developing regions to increase their market share. In addition, they are adopting strategies such as mergers & acquisitions and the development of new products. For instance, in March 2015, Illumina, Inc. collaborated with Merck Serono to develop a universal next-sequencing-based oncology diagnostic.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2018 - 2025
Revenue in USD Million & CAGR from 2014 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
The U.S., Canada, The U.K., Germany, China, Japan, India, Brazil, Mexico, South Africa,
Revenue, company share, competitive landscape, growth factors, trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global epigenetics market report on the basis of product, technology, application, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Chip sequencing kit
Whole Genomic Amplification kit
Bisulfite Conversion kit
RNA sequencing kit
Technology Outlook (Revenue, USD Million, 2014 - 2025)
Large non - coding RNA
Application Outlook (Revenue, USD Million, 2014 - 2025)
Non - oncology
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East and Africa (MEA)
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.